Resources from the same session
3890 - Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial
Presenter: Oleg Gluz
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Abstract
4225 - The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid.
Presenter: Francesco Perrone
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Abstract
5253 - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)
Presenter: Michael Untch
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Abstract
5009 - Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04)
Presenter: Annelot van Rossum
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Abstract
4821 - Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies
Presenter: Giampaolo Bianchini
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Abstract
Poster Discussion session - Breast cancer, early stage - Invited Discussant 189PD and 190PD
Presenter: Marc van de Vijver
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Slides
Webcast
2553 - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
Presenter: Pier Franco Conte
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Abstract
4309 - Randomized Trial of Lisinopril or Carvedilol for the Prevention of Cardiotoxicity in Patients with Early Stage HER2-Positive Breast Cancer Receiving Trastuzumab
Presenter: Pamela Munster
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Abstract
Poster Discussion session - Breast cancer, early stage - Invited Discussant 191PD and 192PD
Presenter: Veronique Dieras
Session: Poster Discussion session - Breast cancer, early stage
Resources:
Slides
Webcast